Literature DB >> 34021411

Current understanding of the epidemiologic and clinical characteristics of optic neuritis.

Masanori Nakazawa1, Hitoshi Ishikawa2, Taiji Sakamoto3.   

Abstract

Optic neuritis is an ocular disorder whose pathogenesis has not been fully determined, although autoimmune mechanisms have been suggested to be involved in its development. In recent years, anti-aquaporin-4 antibody (AQP4-Ab) and anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab) have been shown to play major roles in the development of optic neuritis. Because these two antibodies target different tissues, optic neuritis can be classified by the type of antibody. AQP4-Ab-positive optic neuritis responds poorly to steroid therapy and has a poor prognosis in terms of visual acuity. On the other hand, MOG-Ab-positive optic neuritis responds favorably to steroid therapy but is likely to recur when the dosage of steroids is reduced or discontinued. We first present the high incidence of idiopathic optic neuritis and discuss these relatively newer disease concepts of AQP4-Ab-positive optic neuritis and MOG-Ab-positive optic neuritis.

Entities:  

Keywords:  AQP4; Atypical optic neuritis; MOG; Oral steroid monotherapy; Typical optic neuritis

Year:  2021        PMID: 34021411     DOI: 10.1007/s10384-021-00840-w

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  76 in total

1.  Aquaporins 6-12 in the human eye.

Authors:  Thuy Linh Tran; Toke Bek; Lars Holm; Morten la Cour; Søren Nielsen; Jan Ulrik Prause; Aleksandra Rojek; Steffen Hamann; Steffen Heegaard
Journal:  Acta Ophthalmol       Date:  2012-09-13       Impact factor: 3.761

Review 2.  Optic neuritis.

Authors:  Ahmed T Toosy; Deborah F Mason; David H Miller
Journal:  Lancet Neurol       Date:  2014-01       Impact factor: 44.182

3.  Treatment of optic neuritis with intravenous megadose corticosteroids. A consecutive series.

Authors:  T C Spoor; D L Rockwell
Journal:  Ophthalmology       Date:  1988-01       Impact factor: 12.079

4.  Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial.

Authors:  Sarah A Morrow; J Alexander Fraser; Chad Day; Denise Bowman; Heather Rosehart; Marcelo Kremenchutzky; Michael Nicolle
Journal:  JAMA Neurol       Date:  2018-06-01       Impact factor: 18.302

Review 5.  Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis.

Authors:  Takeshi Kezuka; Hitoshi Ishikawa
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

6.  Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan.

Authors:  Hitoshi Ishikawa; Takeshi Kezuka; Keigo Shikishima; Akiko Yamagami; Miki Hiraoka; Hideki Chuman; Makoto Nakamura; Keika Hoshi; Toshiaki Goseki; Kimiyo Mashimo; Osamu Mimura; Takeshi Yoshitomi; Keiko Tanaka
Journal:  Ophthalmology       Date:  2019-05-06       Impact factor: 12.079

7.  Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group.

Authors:  J L Keltner; C A Johnson; J O Spurr; R W Beck
Journal:  Arch Ophthalmol       Date:  1993-02

8.  Optic neuritis treatment trial. One-year follow-up results.

Authors:  R W Beck; P A Cleary
Journal:  Arch Ophthalmol       Date:  1993-06

9.  Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.

Authors:  Joanna Kitley; M Isabel Leite; Ichiro Nakashima; Patrick Waters; Benjamin McNeillis; Rachel Brown; Yoshiki Takai; Toshiyuki Takahashi; Tatsuro Misu; Liene Elsone; Mark Woodhall; Jithin George; Mike Boggild; Angela Vincent; Anu Jacob; Kazuo Fujihara; Jacqueline Palace
Journal:  Brain       Date:  2012-05-09       Impact factor: 13.501

10.  Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial.

Authors:  Roy W Beck; Robin L Gal
Journal:  Arch Ophthalmol       Date:  2008-07
View more
  1 in total

Review 1.  Update on glial antibody-mediated optic neuritis.

Authors:  Honglu Song; Huanfen Zhou; Shihui Wei
Journal:  Jpn J Ophthalmol       Date:  2022-07-27       Impact factor: 2.211

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.